|
π
|
A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan.
19 auth.
Takeshi Kimura,
K. Kozuma,
K. Tanabe,
S. Nakamura,
M. Yamane,
T. Muramatsu,
S. Saito,
J. Yajima,
N. Hagiwara,
K. Mitsudo,
...
J. Popma,
P. Serruys,
Y. Onuma,
Shih-wa Ying,
Sherry Cao,
P. Staehr,
W. Cheong,
Hajime Kusano,
G. Stone
|
8 |
2015 |
8
π
|
|
π
|
Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial.
19 auth.
Y. Onuma,
Y. Sotomi,
H. Shiomi,
Y. Ozaki,
Atsuro Namiki,
S. Yasuda,
T. Ueno,
K. Ando,
Jungo Furuya,
K. Igarashi,
...
K. Kozuma,
K. Tanabe,
Hajime Kusano,
R. Rapoza,
J. Popma,
G. Stone,
C. Simonton,
P. Serruys,
Takeshi Kimura
|
7 |
2016 |
7
π
|
|
π
|
The XIENCE nanoβ’ everolimus eluting coronary stent system for the treatment of small coronary arteries: The SPIRIT small vessel trial
10 auth.
L. Cannon,
D. Simon,
D. Kereiakes,
Jennifer Jones,
R. Mehran,
Hajime Kusano,
...
Zhen Zhang,
W. Lombardi,
F. James Fleischhauer,
M. Costa
|
5 |
2012 |
5
π
|
|
π
|
Three-Year Clinical Outcomes of Everolimus-Eluting Stents From the Post-Marketing Surveillance Study of Cobalt-Chromium Everolimus-Eluting Stent (XIENCE V/PROMUS) in Japan.
10 auth.
J. Aoki,
K. Kozuma,
M. Awata,
M. Nanasato,
N. Shiode,
K. Tanabe,
...
J. Yamaguchi,
Hajime Kusano,
H. Nie,
Takeshi Kimura
|
5 |
2016 |
5
π
|
|
π
|
SPIRIT III JAPAN versus SPIRIT III USA: a comparative intravascular ultrasound analysis of the everolimus-eluting stent.
16 auth.
T. Shimohama,
J. Ako,
M. Yamasaki,
H. Otake,
I. Tsujino,
T. Hasegawa,
D. Nakatani,
R. Sakurai,
Hyeonsoo Chang,
Hajime Kusano,
...
K. Waseda,
Y. Honda,
G. Stone,
S. Saito,
P. Fitzgerald,
K. Sudhir
|
5 |
2010 |
5
π
|
|
π
|
Randomized Comparison Between Everolimus-Eluting Bioresorbable Scaffold and Metallic Stent: Multimodality Imaging Through 3 Years.
24 auth.
Y. Onuma,
Y. Honda,
T. Asano,
H. Shiomi,
K. Kozuma,
Y. Ozaki,
A. Namiki,
S. Yasuda,
T. Ueno,
K. Ando,
...
Jungo Furuya,
K. Hanaoka,
K. Tanabe,
K. Okada,
H. Kitahara,
M. Ono,
Hajime Kusano,
R. Rapoza,
C. Simonton,
J. Popma,
G. Stone,
P. Fitzgerald,
P. Serruys,
Takeshi Kimura
|
4 |
2020 |
4
π
|
|
π
|
Five-year clinical outcomes of everolimus-eluting stents from the post marketing study of CoCr-EES (XIENCE V/PROMUS) in Japan
11 auth.
J. Aoki,
K. Kozuma,
M. Awata,
M. Nanasato,
N. Shiode,
K. Tanabe,
...
J. Yamaguchi,
Hajime Kusano,
H. Nie,
Takeshi Kimura,
O. B. O. E. investigators
|
4 |
2018 |
4
π
|
|
π
|
Long-Term Outcomes of Absorb Bioresorbable Vascular Scaffold vs. Everolimus-Eluting Metallic Stentγ- A Randomized Comparison Through 5 Years in Japan.
10 auth.
K. Kozuma,
K. Tanabe,
Yuji Hamazaki,
T. Okamura,
Jiro Ando,
Y. Ikari,
...
Y. Nakagawa,
Hajime Kusano,
D. Ediebah,
Takeshi Kimura
|
4 |
2020 |
4
π
|
|
π
|
The impact of coronary calcification on angiographic and 3-year clinical outcomes of everolimus-eluting stents: results of a XIENCE V/PROMUS post-marketing surveillance study
11 auth.
N. Shiode,
K. Kozuma,
J. Aoki,
M. Awata,
M. Nanasato,
K. Tanabe,
...
J. Yamaguchi,
Hajime Kusano,
H. Nie,
Takeshi Kimura,
O. B. O. E. investigators
|
3 |
2018 |
3
π
|
